News and Press

Press releases

Diagonal Bio’s CEO Karin Wehlin increases ownership

Non-regulatory

Diagonal Bio AB’s (”Diagonal Bio” or the ”Company”) CEO, Karin Wehlin, has directly and through Wehlin’s fully owned company WW Advise AB purchased 8,500,000 shares in the Company to a total price of approximately SEK 170,000 (average price SEK 0.02 per share). The acquisition has been made in the market during 11-12 February 2025.  

Read more

Nomination Committee change in Diagonal Bio (publ.)

Non-regulatory

Diagonal Bio announces a change the Nomination Committee for the Annual General Meeting (AGM) on May 20, 2025.

Read more

Nomination Committee appointed for Diagonal Bio

Non-regulatory

Diagonal Bio today announces that the Nomination Committee has been appointed in preparation for the Annual General Meeting (AGM) on May 20, 2025.

Read more

Valberedning utsedd i Diagonal Bio AB (publ) inför årsstämman 2025

Non-regulatory

I enlighet med de principer för inrättande av valberedning som tidigare beslutats på årsstämman 2024, har följande valberedning utsetts för Diagonal Bio AB (publ.) inför årsstämman den 20 maj, 2025.

Read more

Diagonal Bio will present LAMPlify® at a partnered event for trainers at Jägersro

Non-regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) will be participating in a partnered event with Svensk Galopp, at Jägersro on November 7, 2024. The Company’s diagnostic platform, LAMPlify®, will be introduced to a select group of invited trainers.

Read more